Studies of fish oil in people
109 studies gave fish oil to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases remnant lipoprotein cholesterol no change: Has no effect on C-reactive protein | Randomized trial12 weeks | 240 peoplemiddle-aged and elderlyMidlife adults; Older adults | Clinical nutrition (Edinburgh, Scotland), Nov 1, 2026 |
up: Improves climacteric symptoms-39.19% down: Decreases body weight-12.9% down: Decreases HbA1c-13.16% | Randomized trial60 days | 98 peopleWomen47 ± 2 yearsMidlife adults; perimenopausal women receiving nutritional advice adapted to Mediterranean diet | Current Women s Health Reviews, Sep 15, 2026 |
down: Decreases CERT2-2.18, 95% CI -3.15--1.21 | Randomized trial20 weeks | Within a structured cardioprotective dietary program | Journal of clinical lipidology, Sep 9, 2026 |
| Randomized trial24 weeks | 14 people55-75 yearsMidlife adults; Older adults; in patients with MCI | Antioxidants (Basel, Switzerland), May 6, 2026 | |
up: Increases end-diastolic velocitymean difference 1.95 (0.13, 3.77) up: Increases peak diastolic velocitymean difference 2.95 (0.48, 5.41) no change: Has no effect on blood pressure | Randomized trial3-week | 64 peopleIn the left anterior descending artery | Food & function, Mar 31, 2026 |
no change: Has no effect on carotid plaqueOR 0.54 (0.26-1.13) for high-dose; P trend = 0.111 down: Decreases remnant cholesterol down: Lowers the risk of carotid plaqueP for interaction = 0.008; FDR = 0.056 | Randomized trial14 month | 415 peopleOverall cohort | Cardiovascular diabetology, Jan 20, 2026 |
down: Lowers the risk of cardiovascular diseaseHR 0.57, 95% CI 0.47 to 0.70, P<0.001 down: Decreases mortalityHR 0.77, 95% CI 0.65 to 0.90 down: Lowers the risk of myocardial infarctionHR 0.56, 95% CI 0.40 to 0.80 | Randomized trial3.5 years | 1,228 peopleadultMaintenance hemodialysis | The New England journal of medicine, Nov 7, 2025 |
down: Decreases HOMA-IRP < 0.01 up: Increases EPA | Randomized trial12-week | 201 peopleBothover 40 years oldMidlife adults; Older adults; healthy | Food & function, May 13, 2025 |
| Trial4 weeks | 86 people20–70 yearsGeneral population; healthy adults | Lipids in health and disease, Mar 20, 2025 | |
no change: Has no effect on blood lipids down: Decreases migraine | Randomized trial12‐week | 47 people17.0% were male, and 83.0% were female40.32 ± 9.24 years oldIndividuals with episodic migraines | Brain and behavior, Dec 1, 2024 |
up: Increases omega-3 index+52.51% down: Decreases calf pain score up: Improves leg strength | Randomized trial4 weeks | 24 peopleMenPatient cohorts | Journal of sports science & medicine, Jun 1, 2024 |
up: Increases bioavailable ironp < 0.05 | Randomized trial12 weeks | 117 peopleWomenmiddle-agedMidlife adults; Older adults; women with moderate pretreatment hemoglobin levels (tertile 2) | Maturitas, Feb 24, 2024 |
up: Increases cholesterol efflux capacityP = 0.002 versus baseline down: Decreases HDL-associated proteinsP < 0.05 versus baseline up: Increases HDL-associated phospholipid familiesP < 0.05 versus baseline | Trial30 d | 7 peopleyoung adults | The Journal of nutrition, Jan 17, 2024 |
up: Improves upper-body strength5.0 kg, 95%CI: 0.07, 9.93 up: Improves lower-body strength0.31 kg∙kg−1 vs. 0.20 kg∙kg−1 no change: Has no effect on lean body mass+3.4% vs +2.4% | Randomized trial10-week | 21 peopleM: 5, F: 5; M: 5, F: 6between 18 and 40 yearsYoung male and female adults | Journal of the International Society of Sports Nutrition, Dec 1, 2023 |
up: Improves handgrip strength+5.7% vs +2% down: Decreases blood pressure down: Decreases triglyceride | Randomized trial8 wk | 20 peoplewomen65.65 ± 3.39 yHealthy older women | Nutrients, Oct 25, 2023 |
up: Increases skeletal muscle massP < 0.001 up: Improves muscle strengthP < 0.001 up: Improves physical functionP < 0.001 | Randomized trial6 months | 200 peopleolder peopleOlder adults | Age and ageing, Dec 5, 2022 |
up: Improves muscle strength32.5% vs 8.98% no change: Has no effect on muscle cross-sectional area6.11% vs 2.91% | Randomized trial98 days | 34 peoplefemaleaged 65 years or olderSedentary sarcopenic older women | Nutrients, Jul 11, 2022 |
up: Increases cerebrovascular responsiveness to processing speed test4.4% ± 1.9% vs. -2.2% ± 2.1% up: Increases processing speedZ-score 0.6 ± 0.2 vs. 0.1 ± 0.2 | Randomized trial16 weeks | Men50-80 yearsMidlife adults; Older adults; in males only | The Journal of nutrition, Oct 25, 2020 |
| Randomized trial12 weeks | 58 people51.7 ± 1.7 yearsMidlife adults; overweight and obese adults | Nutrients, May 30, 2020 | |
down: Decreases triglyceridep < 0.05 no change: Has no effect on cholesterol | Randomized trial8-weeks | 30 peopleGeneral population | Nutrients, Mar 12, 2020 |
down: Decreases TNF-alpha-1.87 ± 2.71 vs. -0.64 ± 2.62 down: Decreases C-reactive protein-0.85 ± 2.49 vs. 0.56 ± 2.14 no change: Has no effect on IL-6-0.66 ± 1.05 vs. -0.25 ± 0.94 | Randomized trial90 days | 77 peoplemiddle-aged/elderlyMidlife adults; Older adults; change compared with corn oil control group | Food & function, Feb 26, 2020 |
no change: Has no effect on cerebrovascular responsiveness to hypercapnia down: Decreases cerebral artery stiffnessP = 0.007 down: Decreases heart rateP = 0.038 | Randomized trial16-week | 152 peopleMen50-80 yearsOlder adults; in males | Nutrition, metabolism, and cardiovascular diseases : NMCD, Dec 30, 2019 |
up: Increases TGgreater than twofold down: Decreases triglyceride | Randomized trial12 weeks | 9 peopleMenFollowing fish oil intake | European journal of nutrition, Dec 21, 2019 |
down: Decreases IL-8 down: Decreases IL-1β down: Decreases IL-6 | Randomized trial4 weeks | 12 peopleUnder the Lipoplus regimen | Nutrition research (New York, N.Y.), Oct 23, 2019 |
down: Decreases blood pressureSBP -7.8 mmHg, DBP -4.5 mmHg, MAP -5.6 mmHg | Randomized trial12 weeks | 28 peopleBotholder adultsOlder adults | Sports (Basel, Switzerland), Jul 9, 2019 |
down: Decreases insulinp = .04 up: Increases glutathionep = .001 | Randomized trial12 weeks | In type 2 diabetic patients with coronary heart disease | Phytotherapy research : PTR, Jun 13, 2019 |
down: Decreases PGE-M no change: Has no effect on prostaglandin E2 down: Decreases prostaglandin E218% reduction vs 10% increase | Randomized trial24 weeks | 141 peoplebetween the ages of 40 and 80 yearsIndividuals diagnosed with an adenoma | European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), May 1, 2019 |
| Randomized trialSeptember 2017 to January 2018 | 65 peopleGeneral population | Journal of the American College of Cardiology, Apr 30, 2019 | |
no change: Has no effect on executive function up: Increases omega-3 fatty acids no change: Has no effect on gait parameters | Randomized trial26 weeks | 43 peoplemean age 69.4 ± 4.6 yearsOlder adults | BMC geriatrics, Mar 13, 2019 |
no change: Has no effect on liver fat content no change: Has no effect on visceral adipose tissuep > 0.05 | Randomized trial12 weeks | 50 peopleMenMidlife adults | Nutrients, Feb 23, 2019 |
no change: Has no effect on IL-6difference of means -0.020 ± 0.077 (SE); 95% CI -0.171 to 0.132; p = .80 no change: Has no effect on 400-m walking speeddifference of means 0.010 ± 0.017 (SE) m/s; 95% CI -0.025 to 0.044; p = .58 | Randomized trial12 months | 289 peopleBoth≥70 yearsOlder adults; log-transformed plasma IL-6 | The journals of gerontology. Series A, Biological sciences and medical sciences, Dec 13, 2018 |
no change: Has no effect on blood glucose-15.4% change AUC, P = 0.105 | Randomized trial2 h | 16 people8 males and 7 females26.3 ± 5.04 yearsApparently healthy men and women | Scientific reports, Sep 12, 2018 |
no change: Has no effect on weight and fat lossmean body weight reduction 7.5% (CRMR) vs 5.9% (CRMRF) up: Improves lean body mass down: Decreases IL-6mean IL-6 reduction 35% (CRMRF) vs 21% (CRMR) | Randomized trial12 weeks | 93 peopleAs an adjunct to a calorie-restricted diet with meal replacement | Molecular nutrition & food research, Aug 26, 2018 |
no change: Has no effect on inflammatory cytokine production no change: Has no effect on surface markers of immunosenescence up: Increases adverse gastrointestinal events | Randomized trial12 weeks | 37 people40 to 70 yearsMidlife adults; Older adults; HIV-infected adults | Journal of alternative and complementary medicine (New York, N.Y.), May 15, 2018 |
down: Impairs psychomotor speed-0.02, 95% CI: -0.04 to 0.00; d = 0.24, P = 0.03 up: Increases perceived cognitive mistakesd = 0.24; P = 0.003 | Randomized trial18 mo | 390 peopleBoth65-90 yOlder adults | The American journal of clinical nutrition, May 1, 2018 |
no change: Has no effect on cognitive functionP = 0.32 | Randomized trialuntil hospital discharge or postoperative day 10 | 320 peoplemedian 62 yOlder adults; cardiac surgery recipients | The Journal of nutrition, Mar 1, 2018 |
down: Decreases cognitive symptoms up: Increases erythrocyte EPA + DHA | Randomized trial24 weeks | BothelderlyOlder adults; older adults with subjective cognitive impairment | Neurobiology of aging, Dec 12, 2017 |
| Trial6 weeks | 210 peopleGeneral population | Journal of personalized medicine, Nov 6, 2017 | |
down: Decreases telomerase activityp = 0.001 within group; between-group p = 0.003 up: Increases P16 mRNA expressionbetween-group p = 0.028 no change: Has no effect on TNF-α and IL-6 mRNA expression | Randomized trial8 weeks | 72 people30-70 yearsType 2 diabetes | Clinical nutrition (Edinburgh, Scotland), Dec 19, 2016 |
up: Increases maximal isometric torque no change: Has no effect on muscle function no change: Has no effect on muscle anatomic cross-sectional area | Randomized trial18 weeks | 23 peopleWomen70.7 ± 3.3 yearsOlder adults; during lower-limb resistance exercise training | The American journal of clinical nutrition, Nov 16, 2016 |